\
&
Contact us
\
&
Contact us
Published on | 1 hour ago
ProgrammesThe Start-up Grant Agreement (SUGA) governing the start-up phase of EIT Water has now been signed. Its main objective is to establish the governance structures and lay the foundations for long-term financial sustainability in line with the EIT’s model.
EIT Water will take on Europe's most urgent water challenges:
EIT Water will also develop its Strategic Agenda and build a growing pan-European network of partners across the water, marine and maritime sectors, expanding its current partnership.
As part of its start-up phase, it is developing a network of Co-Location Centres across Europe, providing access to its services and the EIT’s Europe-wide network for innovators, students, and entrepreneurs. These centres are located in:
• Headquarters – CLC North: Aarhus, Denmark
• CLC United Kingdom and Ireland: Leeds, United Kingdom
• CLC Central and Baltic: Berlin, Germany
• CLC West: Antwerp, Belgium
• CLC Central and Danube: Vienna, Austria
• CLC South: Sibenik, Croatia
• CLC Iberian Peninsula: Malaga, Spain
• CLC Black Sea: Varna, Bulgaria
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
